Larimar Therapeutics, Inc.
- LRMR
- NASDAQ
- Biotechnology
- Clinical-Stage Biotech
- Rare Disease Therapies
- Cell-Penetrating Peptides
$2.12
Today +6.80%Quote Oct 19, 2026, 08:00 PM UTC
−47.63%over the last month
Max drawdown −48.6%From 1-month high −48.6%3 months −48.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Larimar Therapeutics
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
71
Market value
$220.2M
Quote Oct 19
Floor
$2.08
2.0% below price
Resistance
$2.34
10.5% above price
Price vs analyst targets
8 analysts
Lowest target
$5.00Highest target
$11.00
$5.00Highest target
$11.00
- Price $2.12
- Average target $8.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 277% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about LRMRPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free